Elevated HDL Levels Linked to Poorer Cognitive Ability in Females With Parkinson's Disease

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2021 Jun 28

PMID 34177552

Citations 9

Authors

Megan C Bakeberg

Anastazja M Gorecki

Jade E Kenna

Alexa Jefferson

Michelle Byrnes

Soumya Ghosh

Malcolm K Horne

Sarah McGregor

Rick Stell

Sue Walters

Frank L Mastaglia

Ryan S Anderton

Affiliations

Soon will be listed here.

Abstract

Introduction: Cholesterol levels have been associated with age-related cognitive decline, however, such an association has not been comprehensively explored in people with Parkinson's disease (PD). To address this uncertainty, the current cross-sectional study examined the cholesterol profile and cognitive performance in a cohort of PD patients.

Methods: Cognitive function was evaluated using two validated assessments (ACE-R and SCOPA-COG) in 182 people with PD from the Australian Parkinson's Disease Registry. Total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and Triglyceride (TRG) levels were examined within this cohort. The influence of individual lipid subfractions on domain-specific cognitive performance was investigated using covariate-adjusted generalised linear models.

Results: Females with PD exhibited significantly higher lipid subfraction levels (TC, HDL, and LDL) when compared to male counterparts. While accounting for covariates, HDL levels were strongly associated with poorer performance across multiple cognitive domains in females but not males. Conversely, TC and LDL levels were not associated with cognitive status in people with PD.

Conclusion: Higher serum HDL associates with poorer cognitive function in females with PD and presents a sex-specific biomarker for cognitive impairment in PD.

Citing Articles

Very high high-density lipoprotein cholesterol may be associated with higher risk of cognitive impairment in older adults.

Huang H, Yang B, Yu R, Ouyang W, Tong J, Le Y Nutr J. 2024; 23(1):79.

PMID: 39020341 PMC: 11253464. DOI: 10.1186/s12937-024-00983-9.

Sex-dependent associations of serum BDNF, glycolipid metabolism and cognitive impairments in Parkinson's disease with depression: a comprehensive analysis.

Wang X, Zhou C, Li Y, Yang H, Sun X, Li S J Neural Transm (Vienna). 2024; 131(9):1047-1057.

PMID: 38967809 DOI: 10.1007/s00702-024-02802-1.

The Impact of High-density Lipoprotein Cholesterol (HDL-C) Levels and Risk of Movement Disorders in Patients Taking Antipsychotics.

ODonnell C, Demler T, Trigoboff E, Lee C Innov Clin Neurosci. 2024; 21(4-6):27-30.

PMID: 38938537 PMC: 11208005.

Sex differences in alpha-synucleinopathies: a systematic review.

Raheel K, Deegan G, Di Giulio I, Cash D, Ilic K, Gnoni V Front Neurol. 2023; 14:1204104.

PMID: 37545736 PMC: 10398394. DOI: 10.3389/fneur.2023.1204104.

Gender-specific association of blood lipids and reproductive trajectory with cognitive impairment: A community based cross-sectional study from India.

Khate K, Chaudhary V, Longkumer I, Saraswathy K, Devi N Front Psychol. 2023; 14:1107152.

PMID: 36923148 PMC: 10008908. DOI: 10.3389/fpsyg.2023.1107152.

References

Triantafyllou N, Nikolaou C, Boufidou F, Angelopoulos E, Rentzos M, Kararizou E . Folate and vitamin B12 levels in levodopa-treated Parkinson's disease patients: their relationship to clinical manifestations, mood and cognition. Parkinsonism Relat Disord. 2007; 14(4):321-5. DOI: 10.1016/j.parkreldis.2007.10.002. View

Houser M, Tansey M . The gut-brain axis: is intestinal inflammation a silent driver of Parkinson's disease pathogenesis?. NPJ Parkinsons Dis. 2017; 3:3. PMC: 5445611. DOI: 10.1038/s41531-016-0002-0. View

Parkin S, Gregory R, Scott R, Bain P, Silburn P, Hall B . Unilateral and bilateral pallidotomy for idiopathic Parkinson's disease: a case series of 115 patients. Mov Disord. 2002; 17(4):682-92. DOI: 10.1002/mds.10186. View

Nicoletti A, Vasta R, Mostile G, Nicoletti G, Arabia G, Iliceto G . Gender effect on non-motor symptoms in Parkinson's disease: are men more at risk?. Parkinsonism Relat Disord. 2016; 35:69-74. DOI: 10.1016/j.parkreldis.2016.12.008. View

Tomlinson C, Stowe R, Patel S, Rick C, Gray R, Clarke C . Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010; 25(15):2649-53. DOI: 10.1002/mds.23429. View

Miller I, Cronin-Golomb A . Gender differences in Parkinson's disease: clinical characteristics and cognition. Mov Disord. 2010; 25(16):2695-703. PMC: 3003756. DOI: 10.1002/mds.23388. View

van Exel E, de Craen A, Gussekloo J, Houx P, Bootsma-van der Wiel A, Macfarlane P . Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann Neurol. 2002; 51(6):716-21. DOI: 10.1002/ana.10220. View

Aarsland D, Kurz M . The epidemiology of dementia associated with Parkinson's disease. Brain Pathol. 2010; 20(3):633-9. PMC: 8094858. DOI: 10.1111/j.1750-3639.2009.00369.x. View

Reitz C, Tang M, Schupf N, Manly J, Mayeux R, Luchsinger J . Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch Neurol. 2010; 67(12):1491-7. PMC: 3065942. DOI: 10.1001/archneurol.2010.297. View

10.

Yaffe K, Barrett-Connor E, Lin F, Grady D . Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. 2002; 59(3):378-84. DOI: 10.1001/archneur.59.3.378. View

11.

Henderson V, Guthrie J, Dennerstein L . Serum lipids and memory in a population based cohort of middle age women. J Neurol Neurosurg Psychiatry. 2003; 74(11):1530-5. PMC: 1738219. DOI: 10.1136/jnnp.74.11.1530. View

12.

Giugliano R, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E . Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017; 377(7):633-643. DOI: 10.1056/NEJMoa1701131. View

13.

Tonkin A, Barter P, Best J, Boyden A, Furler J, Hossack K . National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005. Heart Lung Circ. 2005; 14(4):275-91. DOI: 10.1016/j.hlc.2005.10.010. View

14.

Marwarha G, Ghribi O . Does the oxysterol 27-hydroxycholesterol underlie Alzheimer's disease-Parkinson's disease overlap?. Exp Gerontol. 2014; 68:13-8. PMC: 4377123. DOI: 10.1016/j.exger.2014.09.013. View

15.

Marras C, Armstrong M, Meaney C, Fox S, Rothberg B, Reginold W . Measuring mild cognitive impairment in patients with Parkinson's disease. Mov Disord. 2013; 28(5):626-33. PMC: 4524474. DOI: 10.1002/mds.25426. View

16.

Hottman D, Chernick D, Cheng S, Wang Z, Li L . HDL and cognition in neurodegenerative disorders. Neurobiol Dis. 2014; 72 Pt A:22-36. PMC: 4252583. DOI: 10.1016/j.nbd.2014.07.015. View

17.

Schommer J, Marwarha G, Schommer T, Flick T, Lund J, Ghribi O . 27-Hydroxycholesterol increases α-synuclein protein levels through proteasomal inhibition in human dopaminergic neurons. BMC Neurosci. 2018; 19(1):17. PMC: 5883307. DOI: 10.1186/s12868-018-0420-5. View

18.

Kummer B, Diaz I, Wu X, Aaroe A, Chen M, Iadecola C . Associations between cerebrovascular risk factors and parkinson disease. Ann Neurol. 2019; 86(4):572-581. PMC: 6951811. DOI: 10.1002/ana.25564. View

19.

Yasui T, Maegawa M, Tomita J, Miyatani Y, Yamada M, Uemura H . Changes in serum cytokine concentrations during the menopausal transition. Maturitas. 2006; 56(4):396-403. DOI: 10.1016/j.maturitas.2006.11.002. View

20.

Walhovd K, Storsve A, Westlye L, Drevon C, Fjell A . Blood markers of fatty acids and vitamin D, cardiovascular measures, body mass index, and physical activity relate to longitudinal cortical thinning in normal aging. Neurobiol Aging. 2013; 35(5):1055-64. DOI: 10.1016/j.neurobiolaging.2013.11.011. View